AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Discover which cash back cards have no fees. Find your ideal card and enjoy rewards without extra costs.
28,185 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Investors watched Alphabet slide as news of AI talent exits raised questions about leadership and the pace of AI inve...
A veteran market commentator shines a light on a legacy chipmaker as a serious AI play. This analysis weighs the case...
With July 16 earnings just days away, Taiwan Semiconductor is shaping up as a high-conviction play thanks to expandin...
Shopify’s $120 billion revival is unfolding with a burst of revenue and user growth, catching short sellers by surpri...
Two popular U.S. dividend ETFs take different paths to income. This guide breaks down how SCHD and FDVV approach divi...
The stock market often rides policy signals as much as earnings. This piece digs into two decision scenarios that cou...
Petco's WOOF ticker hints at a pet retailer balancing stores, services, and digital growth. This investor guide break...
Quantum computing is moving from theory to real-world profit paths. This guide highlights two stocks and a practical ...
Bumble reports softer user growth and a hefty impairment bill, even as cash flow improves. The AI-driven reboot is dr...
What could Nvidia's stock do by the end of 2026? This article lays out clear scenarios, key drivers, and practical ti...
Today’s move in redwire stock popped today reflects a developing narrative around space infrastructure and NASA's new...